RBC Capital analyst Randall Stanicky maintained a Hold rating on Perrigo Company (NYSE:PRGO) plc on Sunday, setting a price target of $49, which is approximately 9.87% above the present share price of $44.6.
Stanicky expects Perrigo Company plc to post earnings per share (EPS) of -$1.13 for the first quarter of 2021.
The current consensus among 4 TipRanks analysts is for a Hold rating of shares in Perrigo Company, with an average price target of $50.33.
The analysts price targets range from a high of $53 to a low of $49.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $1.21 billion and a net profit of $107.7 million. The company's market cap is $6.09 billion.
According to TipRanks.com, RBC Capital analyst Randall Stanicky is currently ranked with 1 stars on a 0-5 stars ranking scale, with an average return of -1.5% and a 41.20% success rate.
Perrigo Co . Plc is a healthcare company, which engages in the production of over-the-counter consumer goods and specialty pharmaceutical products. It operates through the following segments: Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals. The Consumer Healthcare Americas segment comprises the U.S., Mexico and Canada consumer healthcare business. The Consumer Healthcare International segment includes branded consumer healthcare business primarily in Europe and consumer focused businesses in the U.K., Australia, and Israel. The Prescription Pharmaceuticals refers to the U.S. prescription pharmaceuticals business. The company was founded by Luther Perrigo in 1887 and is headquartered in Dublin, Ireland.